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Background: Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm classified in the myelodysplastic
syndrome/myeloproliferative neoplasm (MDS/MPN) category. Molecular abnormalities are reported in about 90 % of
patients with CMML. ASXL1 and SETBP1 mutations, but not TET2 or SFRS2 mutations are reported to be associated
with prognosis.
Methods: We studied frequency of TET2, SRSF2, ASXL1 and SETBP1 mutations in 145 patients with CMML using
Sanger sequencing, and determined the prognostic factors for OS. We also identified the predictive value of ASXL1
mutations (frameshift and nonsense mutations) through comparing the Mayo Prognostic Model with the Mayo
Molecular Model.
Results: Forty-seven (32 %) had a mutation in TET2, 42 (29 %), a mutation in SRSF2, 65 (45 %), a mutation (nonsense and
frame-shift) in ASXL1 and 26 (18 %), a mutation in SETBP1. Significant variables in multivariable analysis of survival included
ASXL1 (HR = 1.99 [1.20–3.28]; P = 0.007), hemoglobin <100 g/L (HR = 2.42 [1.40–4.19]; P = 0.002) and blood immature
myeloid cells (IMCs) (HR = 2.08 [1.25–3.46]; P = 0.005). When our patients were analyzed using the Mayo Prognostic Model
median OS were not reached, 26 months and 15 months (P = 0.014). An analysis using the Mayo Molecular Model
identified 4 cohorts with median OS of not reached, 70 months, 26 months and 11 months (P < 0.001). Data fitting
using our patients suggest the Molecular Mayo Model has significantly higher survival predictive power compared
with Mayo Prognostic Model (P < 0.001, −2 log-likelihood ratios of 538.070 and 552.260).
Conclusions: There were high frequencies of mutations in TET2, SRSF2, ASXL1 and SETBP1 in patients with CMML.
With the addition of ASXL1 frameshift and nonsense mutations, the Mayo Molecular Model fitted better than Mayo
Prognostic Model of our patients.
Keywords: Chronic myelomonocytic leukemia, Mutation, Prognostic model* Correspondence: zjxiao@hotmail.com
†Equal contributors
1MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, 288
Nanjing Road, Tianjin 300020, China
2State Key Laboratory of Experimental Hematology, Institute of Hematology
and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking
Union Medical College, Tianjin 300020, China
Full list of author information is available at the end of the article
© 2015 Cui et al.; licensee BioMed Central. Thi
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.s is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and laboratory features in 145 patients with
chronic myelomonocytic leukemia
Age in years, median (range) 63(18–85)
Males; n (%) 98(68)
Hemoglobin g/L, median (range) 88.0(43.0–166.0)
WBC (109/L), median (range) 21.88(3.01–117.57)
ANC (109/L), median (range) 7.07(0.30–66.91)
AMC (109/L), median (range) 3.58(1.02–57.72)
Platelets (109/L), median (range) 78(4–1001)
FAB subtypes, n (%)
Myelodysplastic, MD 51(35)
Myeloproliferative, MP 94(65)




ASXL1, n (%) 65(45)
SETBP1, n (%) 26(18)
TET2, n (%) 47(32)
SRSF2, n (%) 42(29)
aAcute leukemic transformation; n (%) 18(14)
aDeaths; n (%) 71(56)
aData of acute leukemic transformation and deaths were limited to 127 patients
because of 15 cases of limited updating and 3 cases of transplantation
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Chronic myelomonocytic leukemia (CMML) is in the
overlap category of myelodysplastic syndrome/myelopro-
liferative neoplasms (MDS/MPN) in the World Health
Organization (WHO) classification. CMML is uncom-
mon with an estimated incidence of 0.4/100,000 pa-
tients/year. In the WHO classification it is defined as
persistent blood monocytes >1 × 109/L, no BCR-ABL1 or
PDGFRA/B mutation, <20 % myeloblasts or promono-
cytes in the blood or bone marrow and dysplasia in one
or more myeloid lineages [1].
Molecular abnormalities are detected in about 90 % of
patients with CMML [2, 3] including TET2 in 50–60 %,
SRFS2 in 40–50 %, ASXL1 in 40–50 % and SETBP1 in
5–10 % [2, 4]. ASXL1 and SETBP1 mutations, but not
TET2 or SFRS2 mutations are reported to be associated
with prognosis [4–7].
Several models are used to predict survival of patients
with CMML including: (1) the MD Anderson prognostic
scoring system (MDAPS) in 213 patients [8]; (2) the
CMML-specific prognostic scoring system (CPSS) in a
large series of 558 patients [9]; (3) the Mayo Prognostic
Model (MPM) in 226 patients [10]; (4) Groupe Francais
des Myelodysplasies (GFM) in 312 patients [4]; (5) the
Mayo Molecular Model (MMM) [11], and etc. A study
from the Mayo Clinic reported no significant association
between ASXL1 mutations (missense, nonsense and
frameshift) and leukemia free survival (LFS) or overall
survival (OS) [10]. In contrast a study of GFM re-
ported a significant association between ASXL1 muta-
tions (nonsense and frameshift) and OS [4]. A second
report from the Mayo Clinic and cooperators in 466
patients using the MMM reported a significant associ-
ation between ASXL1 mutation (nonsense, frameshift)
and LFS and OS [11]. We studied the frequency of
TET2, SRSF2, ASXL1 and SETBP1 mutations in 145
patients with CMML and compared their outcomes




Baseline variable are listed in Table 1. Median age was
63 years (range, 18–85 years) and 98 (68 %) were male.
Applying the WHO classification 84 (58 %) of patients
were identified as CMML-1 and 61 (42 %), as CMML-
2. Applying the FAB classification 51 patients (35 %)
patients were classified as having CMML-MD and 94
(65 %), CMML-MP. Median WBC was 21.88 × 109/L
(range, 3.01–117.57 × 109/L). Median platelets were 78 ×
109/L (4–1001 × 109/L). Median hemoglobin concentration
was 88.0 g/L (43.0–166.0 g/L). Three patients received a
transplant, 13, decitabine and the remainder hydroxyurea
and supportive treatment.Spectrum and correlation of gene mutations
TET2 mutations were detected in 47 (32 %) patients, of
them, 22 were frameshift mutations, 6 nonsense muta-
tions and 19 missense mutations. SRSF2 mutations were
detected in 42 (29 %) patients including 39 missense and
3 frameshift mutations. 74 patients (51 %) had an
ASXL1 mutation including 59 with frameshift mutations
(31 with c.1934dupG; p.G646WfsX12), 6 a nonsense
mutation and 9 missense and synonymous mutations
(the following analysis of ASXL1 mutations only include
the frameshift and nonsense mutations due to the prog-
nostic value of only frameshift and nonsense mutations).
Missense mutations focused on a hotspot area from
D868 to I871 in SETBP1 were detected 26 (18 %) pa-
tients. No mutation in these 4 genes was detected in 38
patients (26 %). Mutations in SRSF2 were more frequent
in CMML-MP than CMML-MD (38 % vs. 12 %; P =
0.001). Similarly, SETBP1 mutations were more common
in patients with CMML-MP compared with patients
with CMML-MD (23 % vs. 8 %, P = 0.023, respectively)
(Fig. 1a). There were no significant differences in muta-
tion frequencies of these four genes between patients
with CMML-1 vs. those with CMML-2 (Fig. 1b). Combi-
nations of mutations according ASXL1 mutational state
are shown in Fig. 2. TET2 and SRSF2 mutations were
Fig. 1 Mutational spectrum of TET2, SRSF2, ASXL1 and SETBP1 stratified by FAB and WHO subtypes. (a) Mutations in SRSF2 and SETBP1 were
more frequent in CMML-MP than CMML-MD. (b) There were no significant differences in mutation frequencies of these four genes between pa-
tients with CMML-1 vs. those with CMML-2
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SETBP1 mutations were frequently concordant (P < 0.001;
Table 2).Associations between baseline variables and mutations
Associations between baseline variables and mutations
are summarized in Table 3. TET2 mutation was asso-
ciated with older age (P = 0.005) and a greater propor-
tion of patients with <10 % bone marrow blasts (P = 0.008).
SRSF2 mutations was also associated with older age
(P = 0.000), higher WBC levels (P = 0.027), higher ab-
solute neutrophil levels (P = 0.008), higher blood
monocyte levels (P = 0.004) and higher hemoglobin
concentration (P < 0.001). There was no significant
difference in baseline variables in patients with and
without ASXL1 or SETBP1 mutations.Fig. 2 Combinations of mutations state of TET2, SRSF2, ASXL1 and
SETBP1 according ASXL1 mutation in 145 patients with CMMLPrognostic impact of mutations
Follow-up data were available for 127 patients (88 %)
with a median follow-up interval of 13 months (range,
1–95 months), 18 patients (14 %) transformed to acute
leukemia and 71 (56 %) died (including 15 cases died
after acute leukemia transformation).
Variables significantly associated with survival in multi-
variable analysis included ASXL1 (HR= 1.99 [1.20–3.28];
P = 0.007) (Fig. 3), hemoglobin <100 g/L (HR = 2.42 [1.40–
4.19]; P = 0.002) and blood immature myeloid cells (IMCs)
(HR = 2.08 [1.25–3.46]; P = 0.005) (Table 4).
To clarify the prognostic impact of ASXL1 muta-
tions on survival we evaluated survival of subgroups
based on the Mayo Prognostic Model and Molecular
Mayo Model. Median survivals using the Mayo Prognostic
Model were not reached, 26 months (95 % CI, 19–34
months) and 15 months (95 % CI, 11–19 months) (P =
0.014) (Fig. 4a). Median survivals using the Molecular Mayo
Model were not reached, 70 months (95 % CI not avail-
able), 26 months (95 % CI, 20–32 months) and 11 months
(95 % CI, 7–15 months) (P < 0.001) (Fig. 4b). Data fitting
using our patients suggest the Molecular Mayo Model has
significantly higher survival predictive power comparedTable 2 Association of gene mutations
P value SETBP1 ASXL1 SRSF2 TET2
TET2 0.113 0.147 0.035 ×
SRSF2 0.823 0.949 ×
ASXL1 0.000 ×
SETBP1 ×
P < 0.05, mutations concomitant
P > 0.05, not significant
Table 3 Gene mutations and clinical characteristics
wt vs mut P value
TET2
Age(>65y), % 36.2 61.2 0.005
BM blasts(>10 %), % 37.8 17 0.008
WBC(109/L), median, range 12.96(3.05–98.03) 16.00(3.01–70.50) 0.961
ANC(109/L), median, range 5.83(0.30–66.91) 8.78(1.12–28.64) 0.617
AMC(109/L), median, range 3.06(1.02–18.00) 3.13(1.06–17.63) 0.874
Hb(g/L), median, range 91.0(43.0–158.0) 88.0(43.0–166.0) 0.409
PLT(109/L), median, range 68.0(3.8–895.0) 87.0(9.0–1001.0) 0.866
SRSF2
Age(>65y), % 24.2 64.1 0.000
BM blasts(>10 %), % 33 26.2 0.361
WBC(109/L), median, range 11.47(3.01–98.03) 21.35(5.06–70.50) 0.007
ANC(109/L), median, range 4.92(0.30–66.91) 13.55(1.75–33.90) 0.008
AMC(109/L), median, range 2.29(1.02–18.00) 3.72(1.16–17.63) 0.004
Hb(g/L), median, range 84.0(43.0–166.0) 106.5(56.0–166.0) 0.000
PLT(109/L), median, range 67.5(3.8–895.0) 100.0(9.0–1001.0) 0.392
ASXL1
Age(>65y), % 52.3 53.8 0.863
BM blasts(>10 %), % 28.8 38.8 0.393
WBC(109/L), median, range 11.47(3.01–92.40) 20.10(3.62–98.03)) 0.123
ANC(109/L), median, range 5.17(0.30–66.91) 10.45(0.46–56.66) 0.052
AMC(109/L), median, range 2.52(1.06–18.00) 3.20(1.02–14.82) 0.082
Hb(g/L), median, range 92.0(44.0–166.0) 87.5(43.0–158.0) 0.187
PLT(109/L), median, range 69.0(6.6–1001.0) 90.5(3.8–633.0) 0.487
SETBP1
Age(>65y), % 57.7 52.1 0.605
BM blasts(>10 %), % 29.4 38.5 0.415
WBC (109/L), median, range 12.69(3.01–98.03) 20.46(6.60–49.10) 0.173
ANC (109/L), median, range 5.50(0.30–66.91) 11.75(2.56–33.90) 0.079
AMC (109/L), median, range 2.62(1.06–18.00) 3.25(1.02–11.03) 0.413
Hb(g/L), median, range 88.5(43.0–166.0) 90.5(52.0–137.0) 0.622
PLT(109/L), median, range 74.25(5.0–1001.0) 118.5(3.8–534.0) 0.337
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ratios of 538.070 and 552.260).
Discussion
Mutations in patients with CMML typically involve epi-
genetic regulator genes, spliceosome component path-
way genes, genes controlling transcription factors and
signaling regulator genes [12, 13]. Itzykson R et al. [3]
have recently demonstrated that patients with increased
variant allelic frequency of TET2 are more likely to
demonstrate granulomonocytic hematopoietic skewing
on the basic of early clonal dominance. The diversecombinations of mutations detected in CMML suggest
multi-step pathogenesis of the disease in some cases. For
example, although TET2 and ASXL1 mutations may be in-
dependent drivers of CMML in some patients [3], com-
bined mutations of TET2 and SRSF2 and of ASXL1 with
SETBP1 are consistent with a two-step ‘linear’ model of
CMML development [14]. The complex and diverse muta-
tion spectrum detected by us and others in patients with
CMML suggest complexity from driver mutation to clonal
evolution to clonal dominance and finally to the disease.
This complex pattern may account for the considerable
clinical diversity of CMML.
Fig. 3 Survival data for 127 patients with CMML stratified by ASXL1
mutational status (frameshift and nonsense mutations only)
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about 80 % of patients with chronic neutrophilic
leukemia (CNL) [15] and in about 25 % of patients
with atypical chronic myeloid leukemia [16]. Mutations in
SETBP1 decrease PP2A activity resulting in increased
proliferation [16, 17]. This increase could explain why pa-
tients with SETBP1 mutations in our study were more
likely to be in the CMML-MP subtype vs. the CMML-MD
subtype.
Patients with SRSF2 mutation were also more likely to
be in the CMML-MP. SRSF2 mutation was also associated
with increased age and a higher hemoglobin concentration
as reported previously [7]. Interestingly, Yoshida K et al.
[18] reported splice-gene mutations introduced into normal
hematopoietic cells cause a proliferation defect in vitro and
a competitive disadvantage in vivo.
ASXL1 regulates epigenetic functions (histone and chro-
matin modification) and transcription. ASXL1 mutations
are detected in patients with myelodysplastic syndrome
(MDS), primary myelofibrosis, CMML and acute myeloid
leukemia. Most ASXL1 mutations are frameshift mutations
[4, 10]. We also found a predominance of frameshift
mutations (31 of c.1934dupG; p.G646WfsX12), 59 vs.
only 6 nonsense mutations. There is controversy
whether c.1934dupG; p.G646WfsX12 is real or is aTable 4 Multivariable overall survival analysis for 127 patients
with CMML
Parameters HR 95%CI P value
Hb < 100 g/L vs ≥100 g/L 2.42 1.40–4.19 0.002
IMCs presence vs absence 2.08 1.25–3.46 0.005
ASXL1 mut vs wt 1.99 1.20–3.28 0.007PCR artifact [19]. However, recent data indicate pa-
tients with c.1934dupG; p.G646WfsX12 have a similar
clinical phenotype to patients with other ASXL1 mu-
tations [4, 20]. Based on these data we consider
c.1934dupG; p.G646WfsX12 bona fide mutations. In
Mayo Clinic study nonsense/frame-shift ASXL1 muta-
tions were associated with worse survival whereas they
were not together with missense mutations [10, 11].
We found nonsense/frame-shift ASXL1 mutations
were significantly associated with survival in the final Cox
model along with hemoglobin concentration <100 g/L and
presence of blood IMCs.
There were several prognostic systems for CMML
based either on the FAB classification of CMML or
using systems designed for other diseases including a
cytogenetics-based risk-stratification [21]. Other prog-
nostic models were developed specifically for patients
with CMML. For example, the MDAPS model uses
data on hemoglobin concentration, blood IMCs, abso-
lute lymphocyte counts (ALC) and percent bone
marrow blasts [22] to define risk categories. The G-
MDAPS, developed for patients with de novo and sec-
ondary MDS, and CMML, uses age, performance
score, platelet level, hemoglobin concentration, bone
marrow blasts, cytogenetics data and RBC-transfusion
state to define risk cohorts [23]. The Mayo Prognostic
Model used WBC count, platelet count, hemoglobin
concentration, and blood IMCs to define risk cohorts.
We tested our survival data against to Mayo Prognos-
tic Model and Mayo Molecular Model to determine
the best fit. We found the Mayo Molecular Model,
with the addition of ASXL1 mutations (nonsense and
frameshift mutations) based on Mayo Prognostic
Model, had better predictive power compared with the
Mayo Prognostic Model.
Conclusions
In summary, we found a high frequency of mutations
in TET2, SRSF2, ASXL1 and SETBP1 in patients with
CMML. Often there were several mutations in a per-
son and we found some significant association be-
tween mutation spectrum and clinical and laboratory
variables. We also found the Mayo Molecular Model
best fitted the survival experience of our patients.
Patients and methods
Patients
A hundred and forty five consecutive patients ≥16 years
of age diagnosed with CMML at 3 centers in China from
January, 2007 to December, 2014 were enrolled. None
received prior therapy or exposed to environmental
carcinogens. Baseline variables at diagnosis or referral
were analyzed and patients classified into CMML-1 or
CMML-2 according to the 2008 WHO criteria [1].
Fig. 4 Survival data for 127 patients with CMML stratified by the Mayo prognostic model and the Molecular Mayo model. (a) Median survivals
using the Mayo Prognostic Model were not reached, 26 months, and 15 months. (b) Median survivals using the Molecular Mayo Model were not
reached, 70 months, 26 months and 11 months
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MD and CMML-MP, respectively) were defined ac-
cording to FAB criteria [24]. The study was approved
by the Ethical Committees of the Institute of
Hematology, Chinese Academy of Medical Sciences
(CAMS) and Peking Union Medical College (PUMC) fol-
lowing principles of the Declaration of Helsinki and all pa-
tients gave written informed consent.
PCR and Sanger sequencing
Genomic DNA was extracted using the AxyPrep blood
genomic DNA Miniprep kit (Axygen Biosciences, AP-
MN-BL-GDNA-250 Union City, CA, USA) from bone
marrow cells. Oligonucleotide primers for TET2 (exon 3
to 17), SRSF2 (exon 1, covering amino acid Pro95),
ASXL1 (exon 12) and SETBP1 (amino acid 800 to 935)
were used described previously [25, 26]. All PCR prod-
ucts were confirmed by 1 % agarose gel, purified using
QIAquick Spin Kit (Qiagen, Santa Clarita, CA, USA)
and sequenced using two ABI PRISM 3730xl DNA Ana-
lyzers (Applied Biosystems, Foster City, CA, USA). Sequen-
cing was bi-directional.
Statistical analyses
Numerical variables are presented as medians and
ranges. Categorical variables are described as counts
and relative frequencies (%). Comparisons between
categorical variables were performed using χ2 tests.
Comparisons between continuous variables were per-
formed using the Mann–Whitney U-test. Survival was
analyzed by the Kaplan–Meier method and compared
using the log-rank test. A Cox model was used to iden-
tify the prognostic variables. The above analyses wereconducted with SPSS version 17.0. The likelihood ratio test
was used to compare the Mayo Prognostic Model [10]
and MMM [11] conducted with SAS 9.3. All P-values
are two-tailed, and statistical significance was set at
P < 0.05.
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